Osteoporosis Treatment Market By Drugs Type (Selective Estrogen Receptor Modulators (SERMs), Rank Ligand (RANKL) Inhibitor, Calcitonin, Hormone Therapy, Parathyroid Hormone-Related Protein (PTHrP) Analog, and Bisphosphonates (Risedronate, Alendronate, Ibandronate, Zoledronic Acid, And Others)), By Route of Administration (Injectable, Oral, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospitals Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI10818 | Publish Date: March 2024 | No. of Pages: 171

Global Osteoporosis Treatment Market By Overview

Osteoporosis is a condition in which body loses too much bone and there is an increase in bone weakness. The individual suffering from osteoporosis is more exposed to bone fractures. Hence, a proper treatment is required to cure and avoid the chances of complications. Osteoporosis is a bone disease which involves a continuing weakening of the bones. Osteoporosis reduces the bone density and often leads to fracture in hip, spine, and wrist etc. Some factors may lead to osteoporosis includes low intake of calcium, vitamin D, and magnesium, genetic factors, excessive alcohol intake, physical inactivity, and eating disorders. Osteoporosis can be treated with various medications such as selective estrogen receptor modulators (SERMs) etc., diet and nutrition, exercise, and lifestyle changes. The Osteoporosis Treatment Market accounted for US$ 11.60 billion in 2020 and is estimated to be US$ 17.68 billion by 2030 and is anticipated to register a CAGR of 4.3%.

Global Osteoporosis Treatment Market By Dynamics

 Launches of new drugs

Launches of new drug in market by key players are expected to create good atmosphere for the growth of osteoporosis market growth. For instance, Teva Pharmaceutical Industries Ltd., a key player in market launched generic version of Actonel (risedronate sodium) Tablets, 5 mg, 30 mg, and 35 mg in U.S. The new launched tablet is indicated for the treatment of osteoporosis in women after menopause.

High rates of Osteoporosis

High rates of osteoporosis are expected to increases demand for osteoporosis treatment drugs and are expected to fuel market growth. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japan are suffering from osteoporosis. Furthermore, the increasing prevalence of ageing population is also expected to increase demand for osteoporosis drugs as old people are more prone to osteoporosis disease. Increasing rate and incidence of osteoporosis is expected to be a major factor which will boost the demand for its treatment products in market in upcoming time period. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japanare suffering from osteoporosis.

Geriatric population is more exposed to osteoporosis diseases. Hence, the increasing rates of geriatric population are also expected to upsurge the demand for osteoporosis treatment products in upcoming period of time. 

Global Osteoporosis Treatment Market By Segmentation

The osteoporosis treatment market has been segmented on the basis of product type, route of administration, distribution channel, and region.

The drugs type segment includes selective estrogen receptor modulators (SERMs), rank ligand (RANKL) inhibitor, calcitonin, hormone therapy, parathyroid hormone-related protein (PTHrP) analog, and bisphosphonates (risedronate, alendronate, ibandronate, zoledronic acid, and others.

On the basis of route of administration, the osteoporosis treatment market has been segmented into injectable, oral and others.

On the basis of distribution channel, the osteoporosis treatment market has been segmented in retail pharmacies, online pharmacies, and hospitals pharmacies.

Regional Insights:      

For detailed understanding of market dynamics, on the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions. For detailed understanding of market dynamics, the Osteoporosis Treatment Market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.        

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Drug Type- Selective Estrogen Receptor Modulators (Serms), Rank Ligand (RANKL) Inhibitor, Calcitonin, Hormone Therapy, Parathyroid Hormone-Related Protein (Pthrp) Analog, And Bisphosphonates (Risedronate, Alendronate, Ibandronate, Zoledronic Acid, And Others.

By Route of Administration- Injectables, Orals and Others

By Distribution Channel- Retail Pharmacies, Online Pharmacies, And Hospitals Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Osteoporosis Treatment Market, By Drugs Type:

  • Selective Estrogen Receptor Modulators (SERMs)
    • Bisphosphonates
      • Alendronate
      • Risedronate
      • Ibandronate
      • Zoledronic Acid
      • Others
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Hormone Therapy
    • Calcitonin
    • Rank Ligand (RANKL) Inhibitor

Osteoporosis Treatment Market, By Route of Administration:

  • Injectable
    • Others
    • Oral

Osteoporosis Treatment Market, By Distribution Channel:

  • Retail Pharmacy
    • Hospitals Pharmacy
    • Online Pharmacy

Osteoporosis Treatment Market, By Region:

  • North America
    • North America Osteoporosis Treatment  Market, By Drugs Type
    • North America Osteoporosis Treatment  Market, By Route of Administration
    • North America Osteoporosis Treatment  Market, By Distribution Channel
    • North America Osteoporosis Treatment  Market, By Country
      • U.S.
      • Canada
      • Europe
        • Europe Osteoporosis Treatment  Market, By Drugs Type
        • Europe Osteoporosis Treatment  Market, By Route of Administration
        • Europe Osteoporosis Treatment  Market, By Distribution Channel
        • Europe Osteoporosis Treatment  Market, By Country
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Switzerland
          • Sweden
          • Rest of Europe
      • Asia-Pacific
        • Asia-Pacific Osteoporosis Treatment  Market, By Drugs Type
        • Asia Pacific Osteoporosis Treatment  Market, By Route of Administration
        • Asia-Pacific Osteoporosis Treatment  Market, By Distribution Channel
        • Asia-Pacific Osteoporosis Treatment  Market, By Country
          • China
          • India
          • Australia & New Zealand
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
        • Latin America Osteoporosis Treatment  Market, By Drugs Type
        • Latin America Osteoporosis Treatment  Market, By Route of Administration
        • Latin America Osteoporosis Treatment  Market, By Distribution Channel
        • Latin America Osteoporosis Treatment  Market, By Country
          • Brazil
          • Mexico
          • Argentina and Chile
          • Rest of Latin America
      • Middle East
        • Middle East Osteoporosis Treatment  Market, By Drugs Type
        • Middle East Osteoporosis Treatment  Market, By Route of Administration
        • Middle East Osteoporosis Treatment  Market, By Distribution Channel
        • Middle East Osteoporosis Treatment  Market, By Country
          • GCC
          • Israel
          • Saudi Arabia
          • UAE
          • Rest of Middle East
      • Africa
        • Africa Osteoporosis Treatment  Market, By Drugs Type
        • Africa Osteoporosis Treatment  Market, By Route of Administration
        • Africa Osteoporosis Treatment  Market, By Distribution Channel
        • Africa Osteoporosis Treatment  Market, By Country
          • North Africa
          • Central Africa
          • South Africa

Global Osteoporosis Treatment Market By Key Players

Key players operating in the  osteoporosis treatment market includes, GlaxoSmithKline Plc., Pfizer Inc., Daiichi Sankyo Company, Limited, Dr. Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co AG, Allergan plc., andAmgen Inc., and Teva Pharmaceutical Industries Ltd. Launches of new drug in market by key players are expected to create good atmosphere for the growth of osteoporosis market growth. For instance, Teva Pharmaceutical Industries Ltd., a key player in market launched generic version of Actonel (risedronate sodium) Tablets, 5 mg, 30 mg, and 35 mg in U.S. The new launched tablet is indicated for the treatment of osteoporosis in women after menopause. High rates of osteoporosis are expected to increases demand for osteoporosis treatment drugs and are expected to fuel market growth. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japan are suffering from osteoporosis. Furthermore, the increasing prevalence of ageing population is also expected to increase demand for osteoporosis drugs as old people are more prone to osteoporosis disease.

Global Osteoporosis Treatment Market By Company Profile

  • GlaxoSmithKline Plc.
    • Business Strategies Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
    • Company Overview
    • Pfizer Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Daiichi Sankyo Company Limited
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Dr. Reddy's Laboratories
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Mylan Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Eli Lilly and Company
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Asahi Kasei Corporation
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • F.Hoffmann La Roche
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Novartis AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Merck & Co AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Allergan plc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Amgen Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • EffRx Pharmaceuticals SA
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview

Global Osteoporosis Treatment Market By Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Preview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drugs Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
  3. Market Dynamics Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
      • Drivers- Restraints Impact Analysis
      • PEST Analysis
      • Porter’s Five Forces Analysis
  4. Market Segmentation, By Drugs Type, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Segment Trends
    • Selective Estrogen Receptor Modulators (SERMs)
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Rank Ligand (RANKL) Inhibitor
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Calcitonin
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Hormone Therapy
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Bisphosphonates
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028

Ø  Alendronate

§  Introduction

§  Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028

Ø  Risedronate

§  Introduction

§  Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028

Ø  Ibandronate

§  Introduction

§  Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028

Ø  Zoledronic Acid

§  Introduction

§  Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028

Ø  Others

§  Introduction

§  Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028

  1. Market Segmentation, Route of Administration, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Segment Trends
    • Injectable
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Oral
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Others
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
  2. Market Segmentation, By Distribution Channel, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Hospitals
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
  3. Global Market, By Region, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Drugs Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Route of Administration, 2018 – 2028
      • Market Size and Forecast (US$ Bn),, By Distribution Channels, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028

Ø  U.S.

Ø  Canada

  1. Latin America
    • Market Size and Forecast (US$ Bn), By Drugs Type, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Route of Administration, 2018 – 2028
    • Market Size and Forecast (US$ Bn),, By Distribution Channels, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028

Ø  Brazil

Ø  Mexico

Ø  Argentina and Chile   

Ø  Rest of Latin America

  1. Europe
    • Market Size and Forecast (US$ Bn), By Drugs Type, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Route of Administration, 2018 – 2028
    • Market Size and Forecast (US$ Bn),, By Distribution Channels, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028

Ø  Germany

Ø  UK

Ø  France

Ø  Russia

Ø  Italy

Ø  Switzerland

Ø  Sweden

Ø  Rest of Europe

  1. Asia Pacific
    • Market Size and Forecast (US$ Bn), By Drugs Type, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Route of Administration, 2018 – 2028
    • Market Size and Forecast (US$ Bn),, By Distribution Channels, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028

Ø  China

Ø  India

Ø  Australia & New Zealand

Ø  Japan

Ø  South Korea

Ø  Rest of Asia Pacific

  1. Middle East
    • Market Size and Forecast (US$ Bn), By Drugs Type, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Route of Administration, 2018 – 2028
    • Market Size and Forecast (US$ Bn),, By Distribution Channels, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028

Ø  GCC

Ø  Israel

Ø  Saudi Arabia

Ø  UAE

Ø  Rest of Middle East

  1. Africa
    • Market Size and Forecast (US$ Bn), By Drugs Type, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Route of Administration, 2018 – 2028
    • Market Size and Forecast (US$ Bn),, By Distribution Channels, 2018 – 2028
    • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028

Ø  North Africa

Ø  Central Africa

Ø  South Africa

  1. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • GlaxoSmithKline Plc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Pfizer Inc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Daiichi Sankyo Company Limited

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Dr. Reddy\'s Laboratories

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Mylan Inc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Eli Lilly and Company

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Asahi Kasei Corporation

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • F.Hoffmann La Roche

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Merck & Co AG

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Allergan plc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Amgen Inc.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • Teva Pharmaceutical Industries Ltd.

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1.  
    • EffRx Pharmaceuticals SA

Ø  Company Overview

Ø  Product Portfolio

Ø  Key Highlights

Ø  Financial Overview

Ø  Business Strategy Overview

  1. Analyst Views
  2. Section
    • Research Methodology
    • About Us
    • Contact

FAQs

The osteoporosis treatment market has been segmented on the basis of product type, route of administration, distribution channel, and region.

Increasing rate and incidence of osteoporosis is expected to be a major factor which will boost the demand for its treatment products in market in upcoming time period.

High cost of drugs might hampers the market

Key players operating in the osteoporosis treatment market includes, GlaxoSmithKline Plc., Pfizer Inc., Daiichi Sankyo Company, Limited, Dr. Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co AG, Allergan plc., andAmgen Inc., and Teva Pharmaceutical Industries Ltd.

North America is expected to account major market share as compared to that of other regions.